{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:00:59Z","timestamp":1760266859659},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.lungcan.2008.04.002","type":"journal-article","created":{"date-parts":[[2008,5,22]],"date-time":"2008-05-22T12:53:21Z","timestamp":1211460801000},"page":"72-76","source":"Crossref","is-referenced-by-count":16,"title":["A phase II study of carboplatin and paclitacel with meloxicam"],"prefix":"10.1016","volume":"63","author":[{"given":"Ryujiro","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Saka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Shindoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimasa","family":"Tanikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Gonda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Imaizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Shimokata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2008.04.002_bib1","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.1988.6.4.633","article-title":"Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer\u2014report of a Canadian multicenter randomized trial","volume":"6","author":"Rapp","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2008.04.002_bib2","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1002\/cncr.21869","article-title":"Changes in the natural history of non-small cell lung cancer (NSCLC)\u2014comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990","volume":"106","author":"Wakelee","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2008.04.002_bib3","first-page":"1087","article-title":"New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions","volume":"4","author":"Bunn","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2008.04.002_bib4","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1200\/JCO.2001.19.13.3210","article-title":"Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group Trial","volume":"19","author":"Kelly","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2008.04.002_bib5","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2008.04.002_bib6","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.1200\/JCO.2005.55.405","article-title":"Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol","volume":"23","author":"Belani","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2008.04.002_bib7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0169-5002(00)00132-X","article-title":"Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung","volume":"30","author":"Hosomi","year":"2000","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2008.04.002_bib8","first-page":"6178","article-title":"Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines","volume":"59","author":"Soriano","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2008.04.002_bib9","first-page":"2443","article-title":"Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents","volume":"8","author":"Hida","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2008.04.002_bib10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lungcan.2008.04.002_bib11","first-page":"1469","article-title":"Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo","volume":"79","author":"Sawaoka","year":"1999","journal-title":"Lab Invest"},{"key":"10.1016\/j.lungcan.2008.04.002_bib12","first-page":"362","article-title":"Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer","volume":"58","author":"Sheng","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2008.04.002_bib13","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0092-8674(00)81433-6","article-title":"Cyclooxygenase regulates angiogenesis induced by colon cancer cells","volume":"93","author":"Tsujii","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.lungcan.2008.04.002_bib14","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/ijc.22720","article-title":"Synergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFN-gamma","volume":"121","author":"Irie","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.lungcan.2008.04.002_bib15","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1158\/1078-0432.CCR-05-0108","article-title":"Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer","volume":"11","author":"Altorki","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2008.04.002_bib16","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2482\/haigan.41.767","article-title":"Dose finding study of carboplatin and weekly paclitaxel for advanced non-small cell lung cancer","volume":"41","author":"Hirabayashi","year":"2001","journal-title":"Jpn J Lung Cancer"},{"key":"10.1016\/j.lungcan.2008.04.002_bib17","doi-asserted-by":"crossref","first-page":"686S","DOI":"10.1200\/jco.2004.22.14_suppl.7282","article-title":"Cyclooxygenase-2 (COX-2) inhibition with meloxicam in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer (NSCLC)","volume":"22","author":"Takahashi","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2008.04.002_bib18","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1200\/JCO.2003.02.563","article-title":"Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation","volume":"21","author":"Belani","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2008.04.002_bib19","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/annonc\/mdj016","article-title":"A randomized phase II trial comparing every 3-weeks carboplatin\/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer","volume":"17","author":"Socinski","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2008.04.002_bib20","first-page":"3767","article-title":"Phase II study of carboplatin and weekly paclitaxel in advanced non-small cell lung cancer","volume":"26","author":"Nakadate","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1016\/j.lungcan.2008.04.002_bib21","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/01243894-200605000-00011","article-title":"Weekly paclitaxel combined with monthly carboplatin in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study","volume":"1","author":"Pujol","year":"2006","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2008.04.002_bib22","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3816\/CLC.2006.n.016","article-title":"Multicenter randomized trial for stage IIIB\/IV non-small-cell lung cancer using every-3-week versus weekly paclitaxel\/carboplatin","volume":"7","author":"Schuette","year":"2006","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.lungcan.2008.04.002_bib23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2005.11.014","article-title":"A phase II study of weekly paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer","volume":"52","author":"Inoue","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2008.04.002_bib24","doi-asserted-by":"crossref","first-page":"4266s","DOI":"10.1158\/1078-0432.CCR-040014","article-title":"Cyclooxygenase as a target in lung cancer","volume":"10","author":"Brown","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2008.04.002_bib25","first-page":"1357","article-title":"Overexpression of COX-2 and a potential clinical application of its inhibitors in lung cancer","volume":"62","author":"Hida","year":"2000","journal-title":"Nippon Rinsho"},{"key":"10.1016\/j.lungcan.2008.04.002_bib26","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1200\/JCO.2003.07.127","article-title":"Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer","volume":"14","author":"Altorki","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2008.04.002_bib27","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1200\/JCO.2006.07.4773","article-title":"Randomized phase II trial of docetaxel\/irinotecan and gemcitabine\/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer","volume":"24","author":"Lilenbaum","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2008.04.002_bib28","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S1470-2045(07)70146-8","article-title":"Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study","volume":"8","author":"Gridelli","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lungcan.2008.04.002_bib29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/pds.1077","article-title":"The withdrawal of rofecoxib","volume":"14","author":"Arellano","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.lungcan.2008.04.002_bib30","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0306-4522(99)00365-6","article-title":"Hyperalgea due to nerve injury: role of prostaglandins","volume":"94","author":"Syriatowicz","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.lungcan.2008.04.002_bib31","doi-asserted-by":"crossref","first-page":"481","DOI":"10.7326\/0003-4819-142-7-200504050-00113","article-title":"The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults","volume":"142","author":"Levesque","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lungcan.2008.04.002_bib32","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1161\/01.CIR.0000132491.96623.04","article-title":"Nonsteroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population","volume":"109","author":"Garcia Rodriguez","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.lungcan.2008.04.002_bib33","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1185\/030079907X210561","article-title":"Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization","volume":"23","author":"Sun","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.lungcan.2008.04.002_bib34","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1161\/01.CIR.0000127578.21885.3E","article-title":"Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults","volume":"109","author":"Solomon","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.lungcan.2008.04.002_bib35","doi-asserted-by":"crossref","first-page":"370S","DOI":"10.1200\/jco.2006.24.18_suppl.7025","article-title":"Eicosanoid modulation in advanced non-small cell lung cancer (NSCLC): CALGB 30203","volume":"24","author":"Edelman","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500208001955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500208001955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T22:04:12Z","timestamp":1588716252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500208001955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S0169500208001955"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2008.04.002","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}